In drug price reform, it’s evolution, not revolution; and the ambiguity of migraine options

Expect some congressional action on drug prices, but not major reform By Gregory Twachtman   Congress seems most likely to pass narrow changes to the Medicare Part D prescription drug program.   You can take the MDedge Podcasts survey by clicking here.   Other news: Migraine therapy efficacy leaves ambiguities Selecting the ideal pharmacologic treatment for migraines remains a challenge because of hard-to-compare real-world evidence.   CBT and antidepressants have similar costs for major depressive disorder But after 5 years of treatment, CBT appears to be more cost-effective.   Geriatric Nutritional Risk Index predicts long-term outcomes in PAD Five-year overall survival ranged from 81% to 23% in concert with PAD patients’ Geriatric Nutritional Risk Index score.   FDA advisory committee supports birth control patch approval Concerns persist regarding pregnancy rates and VTE risk among women with obesity who use the patch.   You can contact the MDedge Daily Medical News by emailing us at [email protected] or following us on Twitter at @MDedgeTweets